Page last updated: 2024-11-06
ibuterol
Description
Ibuterol is a β2-adrenergic receptor agonist. It is a chiral molecule, and the (R)-enantiomer is more potent than the (S)-enantiomer. Ibuterol is a bronchodilator and is used to treat asthma and chronic obstructive pulmonary disease (COPD). It is also used to prevent exercise-induced bronchospasm. Ibuterol is typically administered by inhalation, but it can also be given intravenously. Ibuterol is a relatively safe drug, but it can cause side effects such as headache, tremor, and tachycardia. Ibuterol is a potent bronchodilator that can be used to treat asthma and COPD. It is a relatively safe drug, but it can cause side effects. It is being studied for its potential to treat other diseases, such as cancer and Alzheimer's disease.'
ibuterol: diisobutyrate ester of terbutaline; RN given refers to parent cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 68698 |
CHEMBL ID | 2104339 |
SCHEMBL ID | 118615 |
MeSH ID | M0057475 |
Synonyms (18)
Synonym |
kwd-2058 |
ibuterol |
[3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate |
53034-85-8 |
CHEMBL2104339 |
unii-7v12dup1ce |
ibuterolum [inn-latin] |
ibuterolum |
7v12dup1ce , |
terbutalindiisobutyrat |
einecs 258-311-4 |
kwd 2058 |
2-methylpropanoicacid 5-(2-((1,1-dimethylethyl)amino)-1-hydroxy ethyl)-1,3-phenylene ester |
ibuterol [inn] |
5-(2-(tert-butylamino)-1-hydroxyethyl)-m-phenylene diisobutyrate |
SCHEMBL118615 |
Q27268884 |
DTXSID70866296 |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 7 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 104.15
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 104.15 (24.57) | Research Supply Index | 2.48 (2.92) | Research Growth Index | 4.45 (4.65) | Search Engine Demand Index | 184.36 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 3 (37.50%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (62.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |